Linezolid plasma and intrapulmonary concentrations in critically ill obese patients with ventilator-associated pneumonia: intermittent vs continuous administration

[1] De Pascale G(2012)Severe pneumonia in intensive care: cause, diagnosis, treatment and management: a review of the literature Curr Opin Pulm Med 18 213-221

[2] Bello G(2010)Diagnosis, management and prevention of ventilator-associated pneumonia: an update Drugs 70 1927-1944

[3] Tumbarello M(2011)Increasing consumption of MRSA-active drugs without increasing MRSA in German ICUs Intensive Care Med 37 1628-1632

[4] Antonelli M(2011)Relationship between the MIC of vancomycin and clinical outcome in patients with MRSA nosocomial pneumonia Intensive Care Med 201137 639-647

[5] Vincent JL(2010)Attributable mortality of ventilator-associated pneumonia: respective impact of main characteristics at ICU admission and VAP onset using conditional logistic regression and multi-state models Intensive Care Med 36 781-789

[6] de Souza Barros D(2012)Risk factors and mortality of healthcare-associated and community-acquired Staphylococcus aureus bacteraemia Clin Microbiol Infect 18 862-869

[7] Cianferoni S(2012)Ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus: risk factors and outcome in a large general hospital J Hosp Infect 80 150-155

[8] Meyer E(2012)Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study Clin Infect Dis 54 621-629

[9] Schwab F(2011)Linezolid pharmacokinetics and pharmacodynamics in clinical treatment J Antimicrob Chemother Suppl 4 iv7-iv15

[10] Schroeren-Boersch B(2012)Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients J Antimicrob Chemother 67 2034-2042

[1] De Pascale G(2012)Severe pneumonia in intensive care: cause, diagnosis, treatment and management: a review of the literature Curr Opin Pulm Med 18 213-221

[2] Bello G(2010)Diagnosis, management and prevention of ventilator-associated pneumonia: an update Drugs 70 1927-1944

[3] Tumbarello M(2011)Increasing consumption of MRSA-active drugs without increasing MRSA in German ICUs Intensive Care Med 37 1628-1632

[4] Antonelli M(2011)Relationship between the MIC of vancomycin and clinical outcome in patients with MRSA nosocomial pneumonia Intensive Care Med 201137 639-647

[5] Vincent JL(2010)Attributable mortality of ventilator-associated pneumonia: respective impact of main characteristics at ICU admission and VAP onset using conditional logistic regression and multi-state models Intensive Care Med 36 781-789

[6] de Souza Barros D(2012)Risk factors and mortality of healthcare-associated and community-acquired Staphylococcus aureus bacteraemia Clin Microbiol Infect 18 862-869

[7] Cianferoni S(2012)Ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus: risk factors and outcome in a large general hospital J Hosp Infect 80 150-155

[8] Meyer E(2012)Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study Clin Infect Dis 54 621-629

[9] Schwab F(2011)Linezolid pharmacokinetics and pharmacodynamics in clinical treatment J Antimicrob Chemother Suppl 4 iv7-iv15

[10] Schroeren-Boersch B(2012)Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients J Antimicrob Chemother 67 2034-2042